chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Muscle pain in back; Muscle pain in neck / arms; Dull headache; Intestinal upset; Low grade fever; This case was reported by a consumer and described the occurrence of muscular back pain in a 63-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 3rd September 2019 16:00, the patient received the 1st dose of Shingrix. In September 2019, less than a day after receiving Shingrix, the patient experienced muscular back pain, muscle pain, headache dull, gastrointestinal upset and low grade fever. On an unknown date, the outcome of the muscular back pain, muscle pain, headache dull, gastrointestinal upset and low grade fever were not recovered/not resolved.   It was unknown if the reporter considered the muscular back pain, muscle pain, headache dull, gastrointestinal upset and low grade fever to be related to Shingrix.  Additional details were provided as follows: The patient received the Shingrix and experienced muscle pain in back, neck, arms, dull headache and some intestinal upset. The patient had a low grade fever.  The patient asked if she could take Tylenol or something else to relieve the symptoms.
Mom states in PM of 3/26/01 child non-stop crying, greater than 3 hrs and child was inconsolable. Child seen 3/27/01 by Dr and dx with cough and BSOM and treated.
inactive for about 2 and half days; thought that come down with flu or that had any physical reaction to the vaccination; eczema like patches/had an outburst from the one on the wrist and developed the one from the left knee/flared up two or three weeks after the second dose; it's a larger patch and it gets itchier; it's a larger patch and it gets itchier; This spontaneous case was reported by a consumer and describes the occurrence of MALAISE (inactive for about 2 and half days), INFLUENZA (thought that come down with flu or that had any physical reaction to the vaccination), ECZEMA (eczema like patches/had an outburst from the one on the wrist and developed the one from the left knee/flared up two or three weeks after the second dose), ERYTHEMA (it's a larger patch and it gets itchier) and PRURITUS (it's a larger patch and it gets itchier) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 027B21A and 032M20A) for COVID-19 vaccination.     No Medical History information was reported.   On 05-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced MALAISE (inactive for about 2 and half days), INFLUENZA (thought that come down with flu or that had any physical reaction to the vaccination), ECZEMA (eczema like patches/had an outburst from the one on the wrist and developed the one from the left knee/flared up two or three weeks after the second dose), ERYTHEMA (it's a larger patch and it gets itchier) and PRURITUS (it's a larger patch and it gets itchier). The patient was treated with BIFONAZOLE (TOPICAL [BIFONAZOLE]) at an unspecified dose and frequency. At the time of the report, MALAISE (inactive for about 2 and half days), INFLUENZA (thought that come down with flu or that had any physical reaction to the vaccination), ECZEMA (eczema like patches/had an outburst from the one on the wrist and developed the one from the left knee/flared up two or three weeks after the second dose), ERYTHEMA (it's a larger patch and it gets itchier) and PRURITUS (it's a larger patch and it gets itchier) outcome was unknown.
Pt given vaccine in the morning on 8/22  to her left arm and waited in the store for >15min following vaccine and returned to pharmacy to make purchase and report that she felt "fine".  On 8/24 at 10:30a she return to the pharmacy to report that she had a bad muscle pain in her the arm of the injection and muscle ache across her trunk/torso the following morning and took ibuprofen 200mg twice that day. She also presented her left  arm to show and rash across the upper arm that was ~1-2 inch  below the injection; she said it was a little itchy the previous day, sore, and warm. She added there was "bump" in the middle the rash but it was now gone. The Rph on duty asked if it could be a related to a bug bite but she said she didn't think so.  Later that day the patient went to her PCP's office for a walk-in appt and saw nurse. She said the provider told her to apply cold compress and continue ibu and not to get the 2nd dose for the vaccine.
Patient reported a dusty red color wityh swelling and hardness at injection site 2 days post immunization. Patient is a physician herself and believes that the injection site is infected.
CHEST TIGHTNESS, COUGH, CHEST PAIN, DYSPNEA, NECK TIGHTNESS, PALPITATIONS, MEMORY AND COGNITIVE IMPAIRMENT, MYALGIAS, ARTHRALGIAS - ALL SYMPTOMS ARE PERSITING AND PROGRESSING INITIAL REDNESS AND SORENESS AT INJECTION SITE FOR SEVERAL DAYS
Trouble lifting arm. Gripping issues. Continues to get worse. Began symptoms hours after vaccination and continues to become worse. Pain located at injection site radiates down to elbow to last three fingers.
p/vax pt exp hematuria, shaking & nervousness on days one & two;
red blotches on torso and back; lump on her back and both arms; itchy blotches on torso and back; This non-serious case was reported by a other health professional via sales rep and described the occurrence of red blotches in a elderly female patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis.   In SEP-2023, the patient received Arexvy. In SEP-2023, less than 2 weeks after receiving Arexvy, the patient experienced red blotches (Verbatim: red blotches on torso and back), local swelling (Verbatim: lump on her back and both arms) and pruritus (Verbatim: itchy blotches on torso and back).  The outcome of the red blotches, local swelling and pruritus were unknown.   It was unknown if the reporter considered the red blotches, local swelling and pruritus to be related to Arexvy.     It was unknown if the company considered the red blotches, local swelling and pruritus to be related to Arexvy.   Additional Information: GSK Receipt Date:28-SEP-2023 The healthcare professional reported that a female patient in her 70's received AREXVY about 2 weeks ago and had a lump on her back and both arms, and red, itchy blotches on torso and back. No lot number was provided. No other information provided. The reporter consented to follow up.
5/26 arrives to the hospital and patient states that she was visiting her daughter down in another state several weeks ago.  2 weeks ago, patient's daughter tested positive for Covid which prompted patient to get tested in that state.  Her test was negative.  Patient came back from the state 1 week ago and started to feel symptoms over the last several days including shortness of breath, cough, fevers, chills, and feeling fatigued and rundown. Today she tests positive for COVID-19. She is also septic from foot wound cellulitis, hyperglycemic and hypertensive. She is treated with remdesivir (full course), dexamethasone 6mg daily x 10 days & oxygen (max flow 2L). Foot infection treated with antibiotics. Patient developed rash on chest (may be pemphigus foliaceus?) and blistery wound on buttocks while hospitalized. Patient discharged to home.
HYPERtension & Tachycardia Narrative:  Employee c/o heat racing and not feeling well; rushed to UCC via WC. BP 148/66, HR 108, O2Sat 98%. No other details available. No contact information available.
pt recv vax 28JUL98 & mom reports 31JUl98 pt had hives red blotches, niche/size that come & goes;began on 29JUL98 & cont off & on;DPH given;hives cont;
Patient had TD and pneumococcal injections on 9/7/2021. TD left arm; pneumococcal 23 right arm. Patient now having redness, swelling, and increased warmth in right arm. Measures about the size of an orange. Patient feeling sick to her stomach. Started 9/8/2021. Arm less hard now. Has had chills, no fever. No red streaking. Pain also under the arm. Patient using ice application, TYLENOL.  Possible cellulitis post-vaccination as well as vaccine local reaction suspected. Will continue with TYLENOL as well as cool compress. Antibiotic as directed as well as ZOFRAN for associated nausea. Patient to seek further care if redness spreading or fever develops.  Started ONDANSETRON & DOXYCYCLINE 9/10/21.
Pt received FLULAVAL and when finished, immediately looked pale, fainted and had a small seizure. We made her comfortable and helped her rest and get water after she was ok (approx 5 min). Mother reported a few similar seizures in the past.
Warm reddened area where received PREVNAR 13 vacc. 3cm in diameter, mildly warm, non-tender, not supprative in thigh surrounding injection site. No fever; no signs of infection; rec. cool compresses/MOTRIN.
Deviation from recommended age group; This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Deviation from recommended age group) in a 17-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 016B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 01-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Deviation from recommended age group). At the time of the report, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Deviation from recommended age group) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No relevant concomitant medications were reported. No treatment information was provided.
Low grade headache; Rash area was itching; Rash and tiny bumps on her knee, moved to other leg and other body parts; This spontaneous case was reported by a patient and describes the occurrence of RASH PRURITIC (Rash area was itching), RASH (Rash and tiny bumps on her knee, moved to other leg and other body parts) and HEADACHE (Low grade headache) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 057G20A) for COVID-19 vaccination.     No medical history reported.     On 25-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 29-Jan-2021, the patient experienced RASH PRURITIC (Rash area was itching) and RASH (Rash and tiny bumps on her knee, moved to other leg and other body parts). On 25-Feb-2021, the patient experienced HEADACHE (Low grade headache). At the time of the report, RASH PRURITIC (Rash area was itching), RASH (Rash and tiny bumps on her knee, moved to other leg and other body parts) and HEADACHE (Low grade headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product used was not provided by the reporter. Treatment for the events included oral diphenhydramine and anti-itch cream.
SORENESS; DIARRHEA; DIZZINESS; FEVER; This spontaneous report received from a patient concerned a male of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, administered on 07-MAY-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On 08-MAY-2021, the subject experienced soreness. On 08-MAY-2021, the subject experienced diarrhea. On 08-MAY-2021, the subject experienced dizziness. On 08-MAY-2021, the subject experienced fever. Laboratory data included: Body temperature (NR: not provided) 101 F. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from soreness, fever, diarrhea, and dizziness. This report was non-serious.
I do not know that this was related to the vaccine, but it never happened before.  A few days after vaccination (first dose) I experienced an episode of "scintillating scotoma," a visual hallucination of a large, rainbow-colored flashing zigzag pattern across most of my field of vision. It began gradually, increased within a few minutes and lasted about half an hour. I did some reading on this kind of event and learned it is often associated with migraines--which I have never suffered from and did not in this instance (though I did have a slight, dull headache for an hour or so afterward). I found a discussion board of medical professionals online where someone else, a doctor, reported scintillating scotoma a few days after being vaccinated and he also never experienced it before in his life, and also did not experience a migraine. "Correlation does not equal causation," but possibly worth reporting.  A few weeks later (March 9, same location,when I went in for my second dose, I explained what happened to the volunteer giving me the shot. I believe she was a nurse, probably civilian though possibly military, I don't remember. She said, "Oh, yes, I've heard of that happening." Therefore, apparently it has happened to a few people in connection with vaccination though it appears to be extremely rare.  This effect was not serious, not painful, and not debilitating. It was bizarre and a bit unsettling, but also quite beautiful. If it is connected to the vaccine, it would NOT have caused me any hesitation in getting it. However I was advised by a CDC official to report it. I reported on the V-Safe app that I had a possible side effect; I was called by a CDC person a few days ago (Aug. 30, 2021), told her my story, and she suggested that I fill out this report.
Severe fever, chills, profuse perspiration. Full body musle soreness, joint swelling. Severe headache.
Temperature 7.4 F / Time frame 2 hours / the HCP does not know which lot number was administered to the patient.; This spontaneous report was received from a physician, referring to an unspecified number of patients, of unknown age and gender. The patient's pertinent medical history, current conditions, previous drug reactions or allergies were not reported.   On 30-NOV-2020, the patients were vaccinated with virus vaccine live (oka/merck) (VARIVAX), as prophylaxis (formulations, strengths, doses, vaccination schemes, anatomical sites of vaccination, routes of administration, lot numbers and expiration dates were not provided), as concomitant therapy a sterile diluent (MERCK STERILE DILUENT) was used, that did not undergo temperature excursion. The vaccines administered experienced a temperature excursion of 7.4 degrees Fahrenheit, for a time frame of 2 hours as recorded by a data logger. There was no previous temperature excursion reported.   This case has been considered non-valid due to the lack of patients' identifiers.
This case was reported by a consumer via call center representative and described the occurrence of fever in a female patient who received SHINGRIX for prophylaxis. Previously experienced adverse reactions included cold sores lip (when exposed to shingles). Previously administered products included Shingles vaccine (received on an unknown date). On an unknown date, the patient received the 1st dose of SHINGRIX. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced fever, chills and fatigue. On an unknown date, the outcome of the fever, chills and fatigue were unknown. It was unknown if the reporter considered the fever, chills and fatigue to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. This case was linked with US2018GSK186290, reported by the same reporter.
Headache; Fatigue; Fever; Injection site pain; This is a spontaneous report from a non-contactable consumer (patient). A 55 years old non-pregnant female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, formulation: solution for injection, Lot Number: EN6201) via an unspecified route, administered in Left Arm on 19Feb2021 at 04:30 PM (55-year-old at vaccination) as Dose 1, Single for Covid-19 immunization. The patient was non-pregnant at time of vaccination. The patient's medical history was reported as none. Known allergies was reported as none. The patient's concomitant medications were not reported. Facility type vaccine was reported as Other. The patient had no covid prior vaccination. The patient was not tested for covid post vaccination. The patient had not received any other vaccine within four weeks prior to vaccination. On 19Feb2021 at 12:00 AM, the patient experienced headache, fatigue, fever, injection site pain. No treatment medications received for the resulted events. The outcome of events was recovered on an unknown date in 2021.  No follow-up attempts are possible. No further information was expected.
Tachycardia starting at ~10:30pm on 01/06/2021 that persisted for ~1.5-2 hours. Heart rate in mid to upper 130s for ~1 hour followed by 0.5-1 hour of heart rate in the 110-120s. Also accompanied with flushing and redness of both ears and chills/shivering that resolved in the same timeframe of ~1.5 hours.  (Normal/baseline HR of 65-70bpm at rest).
Held breath after PCV13. Then turn pale and glassy eyed after PEDIARIX.
No additional AEs or PQC reported.; Caller reported expired VAQTA administered.; This spontaneous report was received from a nurse and refers to a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On 18-JAN-2023, the patient was vaccinated with hepatitis a vaccine, inactivated (VAQTA) intramuscular injection, 25/0.5, 0.5 milliliter, lot #W007375, expiration date: 16-JAN-2023, administered intramuscularly for prophylaxis (strength was not provided) (Expired product administered). No adverse event was reported.
Severe allergic rash all over body for 3+ weeks. Have been to urgent care twice, 2 rounds of steroid injections, prednisone pills (taper packs), zyrtec, tylenol, pepcid AC, and aquaphor daily. Very little improvement. Had and recovered from long-term COVID-19 disease in December, 2020 - January 2021.
Pt experienced local reaction post pneumonia shot to R arm redness et induration approx 6cm by 20cm increased warmth, temp increased 101 deg, increased soreness to touch.
After injection developed extreme headache and neck side and back pain. Went to see PCP and was told to take TYLENOL. At this date patient is finally going away.
This spontaneous report was received from a nurse via a company representative concerning two patients of unknown age and gender. On an unknown date, patients were vaccinated with a dose of PNEUMOVAX23 (lot number, expiry date, dose and route unspecified). No concomitant medications were reported. On an unknown date (several months ago), the patients experienced pain and discomfort at the injection site. The nurse informed the representative that the pain was similar but not to the same extent as the other patient (MARRS number 1304USA003687). It was unspecified if the patients sought any medical attention. It was unspecified if any treatment was given or any lab tests were performed. The outcome of pain and discomfort at the injection site was unknown. The relatedness for pain and discomfort at the injection site was unknown for PNEUMOVAX23. This is one of the two reports from the same source. Additional information has been requested.
TENDER AND REDNESS ON THE INJECTION SITE THAT IS PAINFUL- RECOMMENDED TO TAKE BENADRYL AND TYLENOL TO COUNTERACT THE EFFECT AND TO SEE THE DOCTOR RIGHT AWAY.
Patient was sitting in waiting room after shot when she experienced numbing on left side of face, feeling like a Novocaine shot at the dentist, this lasted for 7 hours. Patient came in thew next day to inform us of the event but did not have an other issues.
Systemic: Dizziness / Lightheadness-Medium, Systemic: Flushed / Sweating-Medium, Systemic: Hypotension-Medium, Systemic: Nausea-Medium, Systemic: Tachycardia-Medium, Additional Details: Loss of hearing for a few minutes. EMTs came to store monitored pt and BP for additional 15-20 mins. BP increased to over 100. PT had water, crackers and chocolate. Pt felt fine and refused to be taken by ambulance but had a friend pick her up. I explained situation to friend and pt was told to take it easy for the rest of the day.
Pt. woke up the morning after immunization (approx. 16 hours later) feeling sore "from the top of my head to the tip of my toes". Extremely lethargic, no appetite. No fever.
It stated with a cold, runny stuffy nose, sneezing, headache that lasted a couple days. It progressed to lungs and coughing, it felt like I was getting a fever, I did check, it was a low-grade fever. I went into the doctor's office after the exam and running a PCR COVID-19 test, pneumonia test, influenza A and B test, and RSV test all tests came back negative. I was given a prescription for a Z-PAK that I started that evening and within twenty-four hours I started feeling much better.
tachycardia, syncope, localized itch which had onset of 30-40' & lasted 6 hr;no tx necessary;
Itching, 4-5? red band around arm, hot hard, swelling so far times 4 day.  No treatment. Still have
1st dose 3/9/21- I received the injection at ~6:30pm & these symptoms began on 3/9/21 at ~ 8:30pm & lasted for ~24 hours after receiving the vaccine  ?> Slight swelling & soreness at injection sight (right arm), low grade fever, tiredness, slight nausea  2nd dose 3/31/21 - I received the injection at ~12:35pm & these symptoms began on 3/31/21 at ~2:30pm & are ongoing as of this reporting on 4/2/21 ?> Tightness, large swelling, & extreme soreness at injection sight (left arm), extreme fatigue, headache, severe joint pain all over body, dizziness & feeling faint, severe stabbing pain in left side on back at shoulder blade that became worse with deep breathing or sitting upright, gland swelling on neck
An eight year old child, gender unspecified, experienced fever after vaccination with RabAvert for post exposure prophylaxis. Details regarding the dosing of RabAvert were unspecified; however, the child was known to have received four out of five vaccinations. The child's medical history and concomitant medications were also unspecified. The day prior to receiving the last vaccination with RabAvert, the child developed a fever of 100 degrees F without other symptoms. At the time of this report, the fever remained unresolved. The child was known to have started school recently. The reporter (nurse) assessed the event as not related to RabAvert. Additional information received on 09/17/04: The patient (JB) was an eight year old male. He received RabAvert 1 ml intrmuscularly on day one, three, seven, fourteen and twenty eight (dates unspecified). His last vaccination with RabAvert was due on 09/03/04, however, he presented with fever on 09/02/04 which resulted in the delay of the vaccination till 09/07/04. The event resolved on 09/04/04. The reporter (nurse and the mother) assessed the event as not related to RabAvert.